An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases

被引：4
|
作者：
Hong, Seung Wook [1 ]
Kim, Yong-Gil [2 ]
Ye, Byong Duk [1 ,3 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Rheumatol, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Inflammatory Bowel Dis Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 09期
关键词：
ankylosing spondylitis; arthritis; Crohn's disease; CT-P13; efficacy; infliximab; psoriasis; rheumatoid arthritis; safety; spondylitis; ulcerative colitis; ACTIVE RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; CROHNS-DISEASE; BOWEL-DISEASE; INNOVATOR INFLIXIMAB; MAINTENANCE THERAPY; INDUCTION THERAPY; PHASE-III; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0086
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed. CT-P13, the first biosimilar of reference IFX, was approved by the European Medicines Agency and licensed by the US FDA for use in all indications of IFX. This updated review summarizes all aspects of CT-P13, including pharmacology and pharmacokinetics, and evaluates its efficacy, safety and immunogenicity for all indications based on the results of the latest clinical trials as well as on real-world experiences.
引用
收藏
页码：609 / 623
页数：15
相关论文
共 50 条
  • [21] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
    Guerra Veloz, Maria Fernanda
    Arguelles-Arias, Federico
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Angel Calleja, Miguel
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
  • [22] Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease
    Lim, Ki Jung
    Lee, So Jung
    Kim, Sunghwan
    Lee, Su Yeon
    Lee, Min Seob
    Park, Yoon A.
    Choi, Eun Jin
    Lee, Eun Beom
    Jun, Hwang Keun
    Cho, Jong Moon
    Lee, Soo Young
    Kwon, Ki Sung
    Lim, Byung Pil
    Jeon, Myung-Shin
    Shin, Eui Cheol
    Choi, Yong Sung
    Fudim, Ella
    Picard, Orit
    Yavzori, Miri
    Ben-Horin, Shomron
    Chang, Shin Jae
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (05) : 593 - 602
  • [23] Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product
    Yoo, Dae Hyun
    Oh, Choongseob
    Hong, SeungSuh
    Park, Won
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 : S15 - S24
  • [24] Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Jung, Yoon Suk
    Park, Dong Il
    Kim, Young Ho
    Lee, Ji Hyun
    Seo, Pyoung Ju
    Cheon, Jae Hee
    Kang, Hyoun Woo
    Kim, Ji Won
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) : 1705 - 1712
  • [25] Infliximab biosimilar CT-P13 for inflammatory bowel disease
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06) : 373 - 375
  • [26] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
    Hannah A. Blair
    Emma D. Deeks
    BioDrugs, 2016, 30 : 469 - 480
  • [27] Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease
    Elosua Gonzalez, Alfonso
    Sanz Segura, Patricia
    Oyon Lara, Daniel
    Lopez Garcia, Santiago
    Arroyo Villarino, Maria Teresa
    Alcala Escriche, Maria Jose
    Ollero Domenche, Leticia
    Rodriguez Gutierrez, Cristina
    Nantes Castillejo, Oscar
    MEDICINA CLINICA, 2020, 154 (12): : 475 - 480
  • [28] An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
    Ebada, Mahmoud Ahmed
    Elmatboly, Abdelmagid M.
    Ali, Ahmed Said
    Ibrahim, Ahmed Mohamed
    Fayed, Notila
    Faisal, Ahmed Faisal
    Alkanj, Souad
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (10) : 1633 - 1652
  • [29] Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    Argulles-Arias, F.
    Guerra Veloz, M. F.
    Perea Amarillo, R.
    Vilches-Arenas, A.
    Castro Laria, L.
    Maldonado Perez, B.
    Chaaro, D.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Caunedo Alvarez, A.
    Romero-Gomez, Manuel
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (05) : 1305 - 1312
  • [30] A Review of CT-P13: An Infliximab Biosimilar
    Kate McKeage
    BioDrugs, 2014, 28 : 313 - 321
12345